Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Orthovita presses on with US kyphoplasty trial:

This article was originally published in Clinica

Executive Summary

Orthovita has completed the patient-enrolment phase of its second US pilot study evaluating its Cortoss biomaterial as a treatment for vertebral compression fractures of the spine. The 20-patient, four-centre study is assessing use of the synthetic cortical bone void filler during kyphoplasty. With kyphoplasty, an inflatable bone tamp is used to restore vertebral height and create a void into which the biomaterial can be injected percutaneously to stabilise the fracture and restore load-bearing capability. Another US trial testing Cortoss in spinal fractures is also underway, notes the Malvern, Pennysylvania firm. It is testing use of the biomaterial during vertebroplasty, whereby Cortoss is injected directly into the vertebral body. Cortoss is already approved in Europe for treating vertebral compression fractures.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT058794

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel